Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome

OBJECTIVES: To describe the methodology and implications of the patient‐identified most bothersome symptom (PI‐MBS) measure used in the phase 3, multicenter, randomized, double‐blind, placebo‐controlled, and parallel‐group PROMISE‐2 trial and to evaluate the contribution of this measure to the asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B., Dodick, David W., Ailani, Jessica, McGill, Lora, Hirman, Joe, Cady, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251621/
https://www.ncbi.nlm.nih.gov/pubmed/34013992
http://dx.doi.org/10.1111/head.14120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251621/
https://www.ncbi.nlm.nih.gov/pubmed/34013992
http://dx.doi.org/10.1111/head.14120

Ejemplares similares